Abstracts tagged "Patient reported outcomes"

Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…
Abstract Number: 2063 • ACR Convergence 2022
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Alfredo Aguirre¹, Kimberly DeQuattro², Patricia Katz³, Kurt Greenlund⁴, Kamil Barbour⁴, Caroline Gordon⁵, Cristina M Lanata⁶, Lindsey Criswell⁷, Maria Dall'Era⁸ and Jinoos Yazdany⁹, ¹University of California, San Francisco, San Francisco, CA, ²University of Pennsylvania, Philadelphia, PA, ³UCSF, San Rafael, CA, ⁴Centers for Disease Control and Prevention, Atlanta, GA, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁶NIH/NHGRI, Washington, DC, ⁷National Human Genome Research Institute, NIH, Bethesda, MD, ⁸University of California, Division of Rheumatology, San Francisco, CA, ⁹UCSF, San Francisco, CA
Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…
Abstract Number: 0199 • ACR Convergence 2022
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
Peter Taylor¹, Frank Behrens², Philip J Mease³, Dieter Wetzel⁴, Paul Peloso⁵, Nicolai Brun⁴, Brian Wiens⁶, Jan Brandt-Juergens⁷, Edit Drescher⁸, Eva Dokoupilova⁹, Anna Rowińska-Osuch¹⁰, Nadia Abdel- Kader Martin¹¹ and Kurt de Vlam¹², ¹University of Oxford, Oxford, United Kingdom, ²Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Affibody AB, Solna, Sweden, ⁵ACELYRIN, Naples, FL, ⁶ACELYRIN, Inc., Los Angeles, CA, ⁷Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁸Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, ⁹Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, ¹⁰ETG Network - Rheumatology, Warsaw, Poland, ¹¹Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, ¹²University Hospitals Leuven, Leuven, Belgium
Background/Purpose: Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a…
Abstract Number: 0377 • ACR Convergence 2022
Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Maria Angeles Puche Larrubia¹, lourdes Ladehesa-Pineda², María Dolores López Montilla², Raquel Granados³, Eduardo Collantes⁴ and Clementina Lopez-Medina⁵, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁵Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: The prevalence of late-onset Psoriatic Arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 0954 • ACR Convergence 2022
What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries
Yvette Meissner¹, Nathalie Costedoat-Chalumeau², Rebecca Fischer-Betz³, Frauke Foerger⁴, Anna Molto⁵, Marianne Wallenius⁶ and Anja Strangfeld¹, ¹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²Inserm DR Paris 5, Paris, France, ³Uniklinik Duesseldorf, Duesseldorf, Germany, ⁴Inselspital Bern, Bern, Switzerland, ⁵Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁶St. Olav University Hospital, Trondheim, Norway
Background/Purpose: The patient reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) includes the six components fatigue, neck, back or hip pain, pain or swelling in…
Abstract Number: 1345 • ACR Convergence 2022
Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
Jonah Levine, Medha Barbhaiya, Vivian Bykerk, Deanna Jannat-Khah, DrPH, MSPH and Lisa Mandl, Hospital for Special Surgery, New York, NY
Background/Purpose: The SARS-CoV-2 pandemic is a worldwide mental health crisis. We evaluated perceived stress in patients seeking care for musculoskeletal conditions, and explored associations with…
Abstract Number: 1495 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…
Abstract Number: 2069 • ACR Convergence 2022
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Aarabi Thayaparan¹, Patricia Katz², Mitra Moazzami³, Dennisse Bonilla¹, Lisa Engel⁴, Jiandong Su¹, Pooneh Akhavan⁵, Sherief Marzouk⁶, Nathalie Rozenbojm⁷, Nicole Anderson¹, Oshrat Tayer-Shifman⁸, Dorcas Beaton⁹ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²UCSF, San Rafael, CA, ³George Washington University, Washington, DC, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada, ⁸Meir Medical Center, Kfar Saba, Israel, ⁹Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Clinicians should include Patient-Reported Outcome (PRO) measures in the assessment of lupus patients, as they are crucial in providing patient-centred care. The Patient Reported…
Abstract Number: 0200 • ACR Convergence 2022
Should Independence Play a Role in Assessing Remission in Rheumatoid Arthritis?
Thomas Khoo¹, Bethan Jones², Athena Chin¹, Alice Terrett³, Marieke Voshaar⁴, Wijnanda Hoogland⁵, Lyn March⁶, Dorcas Beaton⁷, Ummugulsum Gazel⁸, Beverley Shea⁹, Peter Tugwell¹⁰, Caroline Flurey¹¹ and Susanna Proudman¹², ¹Rheumatology Unit, Flinders Medical Centre, Adelaide, Australia, ²School of Healthcare and Social Wellbeing, University of the West of England, Bristol, United Kingdom, ³Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Pharmacy and Department of Research & Innovation, Sint Maartenskliniek and Department of Pharmacy, Radboud University Medical Centre, Nijmegan, Netherlands, ⁵OMERACT Patient Research Partner, Netherlands, ⁶Sydney Medical School, Institute of Bone and Joint Research, and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia, ⁷Institute for Work & Health, Toronto, ON, Canada, ⁸University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ⁹School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada, Ottawa, Canada, ¹⁰University of Ottawa, Ottawa, Canada, Ottawa, ON, Canada, ¹¹Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ¹²Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: The current goal of treatment in rheumatoid arthritis (RA) is clinical remission, which according to the ACR/EULAR 2011 definition, is based on tender and…
Abstract Number: 0391 • ACR Convergence 2022
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
William Tillett¹, Alexander Egeberg², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
Abstract Number: 0719 • ACR Convergence 2022
Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Lauren Stevens¹, Kyra Mulder², Zhaohui Su², Pam Kumparatana², Jessica Paulus² and Stefan Weiss³, ¹OM1, Inc., Lexington, KY, ²OM1, Inc., Boston, MA, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: Patient-reported outcomes (PROs) are being increasingly utilized in clinical trials to assess the impact of treatment on symptom control and patient quality of life.…
Abstract Number: 1013 • ACR Convergence 2022
Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care
Uta Kiltz¹, Anna Molto², Clementina Lopez-Medina³, Maxime Dougados⁴, Désirée van der Heijde⁵, Annelies Boonen⁶, Filip Van den bosch⁷ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, ³Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁶Maastricht University Medical Centre, Maastricht, Netherlands, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Improvement in functioning and health as assessed by the ASAS Health Index (HI) is an important outcome of interventions in patients with axial spondyloarthritis…
Abstract Number: 1347 • ACR Convergence 2022
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Cristina Arriens¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
Abstract Number: 1497 • ACR Convergence 2022
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Karolina Benesova¹, Oliver Hansen², Uta Kiltz³, Jan Brandt-Juergens⁴, Peter Kästner⁵, Elke Riechers⁶, Daniel Peterlik⁷, Christina Budden⁷, Annika Boas⁷, Stefanie Welle⁷ and Hans-Peter Tony⁸, ¹University Hospital Heidelberg, Heidelberg, Germany, ²Medizinische Abteilung V - Rheumatologie, Universitätsklinikum, Heidelberg, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁶Medizinische Hochschule Hannover, Hannover, Germany, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: In both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].